Psychedelics: Science, Therapy, and the Human Mind
Summary
Matthew Johnson, a leading psychedelics researcher at Johns Hopkins, provides a comprehensive overview of psychedelics — from their pharmacology and safety profiles to their therapeutic potential and the neuroscience of addiction. The conversation covers classic psychedelics like psilocybin and LSD, the unique properties of DMT, and behavioral economic frameworks for understanding addiction.
Key Takeaways
- Classic psychedelics (psilocybin, LSD, mescaline, DMT) are physiologically extraordinarily safe — there is no known lethal overdose for most healthy people, unlike nearly every other psychoactive substance including caffeine and aspirin.
- Classic psychedelics are non-addictive, which is nearly unprecedented among substances people choose to take recreationally.
- The primary risk of psychedelics is “behavioral toxicity” — doing something dangerous (e.g., wandering into traffic) while severely intoxicated, not organ damage or overdose.
- Set and setting matter enormously: the prior beliefs, language, and cultural frameworks a person brings into an experience strongly color its content.
- Psilocybin and LSD show strong therapeutic promise for addiction, depression, and cancer-related anxiety, with research increasingly well-funded through philanthropy.
- DMT and 5-MeO-DMT represent the most extreme end of the psychedelic spectrum, producing experiences of ego dissolution and entity encounters far beyond typical high-dose psilocybin or LSD sessions.
- Addiction is best understood through two lenses: the relative reward value of a substance compared to other life rewards, and delayed discounting (the tendency to overvalue immediate rewards vs. long-term consequences).
- Nicotine/tobacco is the most dangerous drug in modern society by mortality, killing ~500,000 Americans annually — four times more than alcohol.
- Post-experience neuroplasticity in the days following a psychedelic session may be key to its therapeutic effects, though this remains under active study.
Detailed Notes
What Are Psychedelics?
Classic psychedelics share a common mechanism of action:
- They act as agonists at the serotonin 2A receptor
- Includes: psilocybin (mushrooms), LSD, DMT (ayahuasca, smoked), mescaline (peyote, San Pedro cactus)
- Can be organized chemically as phenethylamines, tryptamines, and ergolines — but receptor activity is the more meaningful classification
Broader psychedelics (different pharmacology, overlapping subjective effects):
- MDMA: works presynaptically, flooding synapses with serotonin; more addictive than classic psychedelics but far less than cocaine; carries real risk of long-term serotonin system damage at high/frequent doses
- Ketamine, PCP, ibogaine: distinct mechanisms, sometimes grouped informally as psychedelics
- Cannabis: historically called a “minor psychedelic,” particularly in naive users
What unifies all psychedelics: strong alteration of one’s sense of reality and sense of self.
Safety Profile of Classic Psychedelics
- No known lethal dose for psilocybin or LSD in otherwise healthy individuals
- A person could theoretically take 1,000x the effective dose without organ damage, respiratory depression, or death
- Contrast: aspirin, caffeine, cocaine all have well-defined lethal doses
- Exception: modest cardiovascular effects (slight blood pressure increase) — a risk for people with severe heart disease
- Main risk: behavioral toxicity — acting dangerously while profoundly intoxicated
- Classic psychedelics are non-addictive; daily use is essentially unheard of, unlike nearly all other psychoactive substances
DMT and 5-MeO-DMT
- Represent the most extreme psychedelic experiences available
- Smoked/vaporized DMT onset: effects begin within seconds of first exhalation; full “breakthrough” typically requires ~3 large inhalations
- Progression is described as acceleration from zero to peak experience in seconds — faster than any other route
- Breakthrough dose: transition from “profoundly altered but still in this reality” to a seemingly separate reality
- Common reports: encounters with autonomous entities (described variously as elves, aliens, animals, or abstract beings); communication; sense of receiving information from a higher intelligence
- Johnson’s interpretation: entity encounters likely reflect archetypal psychological structures colored by cultural priors, not necessarily literal external beings — possibly the mind’s use of metaphor to process overwhelming information
- The experience is fully memorable throughout, unlike anesthetics or high-dose alcohol, which cause amnesia
- 5-MeO-DMT is considered by many experienced users to be orders of magnitude more intense than standard DMT
Therapeutic Applications
- Current research focus: treating addiction (smoking cessation), depression, PTSD (MDMA), and cancer-related existential distress
- Most funding is philanthropic (not government-sourced)
- Key insight from cancer patient research: patients “knew” intellectually they should embrace life, but a psilocybin session allowed them to feel it — a distinction between cognitive knowledge and embodied understanding
- Integration (the period after a session) is considered critical to therapeutic outcomes; this is when insights are processed and applied
- Post-session neuroplasticity has been observed in animals and is suspected in humans, possibly underlying therapeutic effects
- Johnson has received a grant from the Heffter Research Institute for an upcoming LSD study
Psychedelics and Creative/Cognitive Enhancement
- Historical anecdotes: Kerry Mullis (Nobel Prize, PCR inventor) credited psychedelic experiences; silicon valley culture widely influenced by psychedelics
- Early (late 1960s–70s) research gave architects and engineers moderate doses (~100 mcg LSD) and had them work on unsolved problems — results were promising but methodologically weak
- Proposed mechanism: reduction of entrenched heuristics and prior assumptions; increased mental flexibility and openness
- Risk: also produces false positives — connecting dots that shouldn’t be connected
- Johnson’s hypothesis: high-dose sessions followed by integration (not working during the session) are likely most valuable for creative breakthroughs
- Language and conceptual frameworks brought into the experience (“priors”) heavily shape what insights emerge
The Neuroscience of the Psychedelic Experience
- Psychedelics cause massively atypical communication between brain regions that don’t normally communicate
- This increased connectivity may underlie both novel insights and false positives
- Experiences resist verbal description; measurement relies on psychometrically validated questionnaires
- Ego dissolution: loss of the psychological construct of self; more common with classic psychedelics and especially DMT/5-MeO-DMT; rare with MDMA
- Ontological shifts (e.g., toward idealism or belief in consciousness as fundamental) are possible but are likely influenced heavily by a person’s prior worldview
Addiction: A Behavioral Economics Framework
Two core dimensions of addiction:
-
Relative reward value: How does the substance compete with other rewards (relationships, career, health)? Addiction emerges when drug reward consistently dominates over pro-social rewards.
-
Delayed discounting: The tendency to devalue future rewards relative to immediate ones. Addicted populations show steeper hyperbolic discounting curves — preferring smaller immediate rewards over larger delayed ones.
- Humans and most animals discount hyperbolically (not exponentially), causing preference reversals: the same person sincerely wants to quit when in a therapist’s office, then sincerely wants to use when the drug is immediately available.
- This explains the “snooze button” phenomenon and why self-control is easier at the grocery store than in front of an open fridge.
Key insight: Addiction is not simply “high reward” but relative reward in the context of available alternatives. Poverty, lack of employment, and lack of education reduce competing rewards, making substances relatively more rewarding.
Drug Policy
- Nicotine/tobacco is the deadliest drug by far: ~500,000 US deaths/year, ~5–6 million globally — 4x more than alcohol
- Heavy taxation of cigarettes reduces adolescent smoking but can harm low-income, deeply addicted users by consuming income without reducing use
- Safe injection sites are supported by public health data; no credible evidence they increase initiation of